Parallel Regulatory Planning Advances Phase IIa Rare Neurology Study in South Korea

Overview

A U.S.-based biotech developing an investigational antibody therapy for rare autoimmune neurological and psychiatric diseases partnered with Novotech to support a Phase IIa study in South Korea.

The sponsor needed to advance an ultra-rare disease program while pursuing development-stage orphan drug designation with the Ministry of Food and Drug Safety (MFDS). Novotech integrated orphan drug designation planning into the IND pathway, preparing the designation package in parallel with ongoing regulatory query resolution.

Following IND approval on March 17, 2026, the orphan drug designation application was submitted on April 16 and approved on April 30, with no additional queries during review. First participant dosing followed on June 9, 2026.

The challenge

The sponsor was advancing a Phase IIa program in an ultra-rare indication while pursuing development-stage orphan drug designation in South Korea.

Three factors made the regulatory pathway particularly demanding:

• Korea-specific requirements: Global development documents needed to be aligned with MFDS expectations, including responses to chemistry, manufacturing and controls (CMC) questions.
• Timing: The sponsor wanted to move from IND approval to orphan drug designation without unnecessary delays between regulatory milestones.
• Decision visibility: The sponsor needed clear, responsive communication about MFDS questions, response strategy and potential timeline implications.

Recruitment planning also had to reflect the limited eligible population and the possibility of adding Australia if additional recruitment capacity was needed.

Novotech’s approach

Planning orphan drug designation alongside IND review

Novotech began preparing the orphan drug designation package while IND queries remained open. This allowed the sponsor to submit the designation application 30 days after IND approval without waiting until the IND process had concluded to begin preparation.

Addressing Korea-specific regulatory requirements

Novotech aligned global development materials with Korean regulatory requirements and supported a risk-based response to an MFDS chemistry, manufacturing and controls query without additional data generation. This avoided an additional data-generation cycle while keeping the regulatory pathway moving.

Maintaining sponsor visibility across workstreams

Novotech coordinated sponsor stakeholders, investigators and MFDS across the parallel regulatory workstreams. Regular communication kept the sponsor informed of agency questions, response strategy and timeline implications.

Novotech also supported the wider Phase IIa program across project management, monitoring, regulatory start-up, medical and safety monitoring, data management and biostatistics, connecting regulatory strategy with ongoing clinical delivery.

Partnership Continues from Phase I to Phase IIa

The sponsor continued its work with Novotech from Phase I into Phase IIa, retaining a team already familiar with the program while adding the Korea-specific regulatory support required for the next stage of development.

Sponsor feedback highlighted Novotech’s MFDS guidance, responsiveness, IND query resolution and coordination across regulatory and clinical activities.

For an ultra-rare program, the result was more than an isolated regulatory approval. By connecting IND resolution, orphan drug designation and clinical delivery, Novotech helped the sponsor reach first participant dosing with the Korean designation already secured.